The CUMBRE Alliance seeks to improve heart disease care in Mexico
An unprecedented alliance, called CUMBRE, made up of 10 leading companies in health innovation, aims to help transform and improve care for cardiovascular diseases (CVD) in Mexico. The collaboration to mitigate the fundamental barriers to heart failure in Mexico arises from the union of the leading players in the health industry in the cardiovascular area in Mexico: the firms AstraZeneca, Bayer, Alianza Boehringer Ingelheim – Lilly, Medtronic, Moksha8, Novartis, Roche, and Servier.
“Our vision to change the paradigms on the care of cardiovascular diseases focuses on achieving a Mexico with greater awareness of the serious problems and challenges that Mexican families face when caring for a person with a heart disease,” he explained. Guillermina Muñoz, medical director of Boehringer Ingelheim, on behalf of the members of CUMBRE.
“In addition to providing information for an adequate quality of life that promotes self-care, we must improve timely, complete, and comprehensive care for the population that already lives with this condition,” he added.
Muñoz pointed out that the problem becomes relevant because in Mexico, as in many parts of the world, “cardiovascular diseases are one of the main causes of death in the population and represent a great challenge in health systems.”
He added that the care that each person gives to their well-being must be paramount “because risk factors such as hypertension, diabetes, and obesity, among others, are the main factors that determine health conditions.”
He pointed out that only 70% of the adult population in Mexico lives with at least one cardiovascular risk factor.
For this reason, the alliance arises with the firm will to “generate significant changes in the care of cardiovascular diseases throughout the Latin American country,” The first step is to unite the industry to generate a synergy of work for the people who live with this condition.
Likewise, the alliance seeks close collaboration with health institutions, the medical community, and organized civil society to provide information, propose care alternatives, and seek comprehensive and sustainable solutions to cardiovascular diseases for the benefit of the population.
“We are convinced that, through the universal collaboration of the leading companies in cardiovascular innovation, as the main ally of health care for the Mexican population, we can make a significant change. We want to make a call to address this public health problem,” said Héctor Orellana, general director for Latin America North of Medtronic.
The major issues for the further development of the pharmaceutical market will be discussed at the Mexican Pharmaceutical Forum that will be organized by the Global Pharmaceutical Leaders’ Club on the 29-30th November 2022 in Mexico City. Secure your delegate place ASAP! Registration is here: https://mexicanpharmaforum.com/registration/
Takeda appoints Hernán Porcile as its new General Manager in Mexico
October 24, 2022
Solid growth of the Medical Devices sector in Mexico
October 19, 2022
Sandoz Receives Certification for Transparent Practices
October 19, 2022